Strategies for prevention of toxicity caused by platinum-based chemotherapy: Review and summary of the Annual Meeting of the Blood-Brain Barrier Disruption Program, Gleneden Beach, Oregon, March 10, 2001

被引:49
作者
Blakley, BW
Cohen, JI
Doolittle, ND
Muldoon, LL
Campbell, KC
Dickey, DT
Neuwelt, EA
机构
[1] Oregon Hlth & Sci Univ, Dept Neurol & Neurosurg, Portland, OR 97201 USA
[2] Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA
[3] Univ Manitoba, Dept Otolaryngol, Winnipeg, MB, Canada
[4] So Illinois Univ, Sch Med, Dept Surg, Springfield, IL 62794 USA
[5] Blood Brain Barrier Disrupt Consortium, Springfield, IL USA
关键词
D O I
10.1097/00005537-200211000-00016
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objectives. To summarize the findings relevant to otolaryngology from the annual meeting of the Blood-Brain Barrier Disruption Consortium in Gleneden Beach, Oregon, March 10, 2001. Study Design: Summaries are provided by the speakers, as well as related data from the published literature. Findings in otology and oncology regarding ototoxicity that were discussed at the meeting are included. Results: Data considered included physiological research, animal studies, and clinical trials that relate to platinum-based chemotherapy and prevention of toxicity. Conclusions: The dose-limiting side effects of platinum-based chemotherapy are preventable, but questions about the effect of the protective agents on oncological efficacy remain. Strategies for prevention of chemotherapy-induced toxicity include temporal or anatomical separation of cisplatin or carboplatin from sodium thiosulfate, D-methionine, or N-acetyl-cysteine. Clinical application of these methods has begun. The mechanisms presumably involve free radicals or drug conjugation, or both. Understanding the role of free radicals in medicine is likely to become important in the future.
引用
收藏
页码:1997 / 2001
页数:5
相关论文
共 44 条
  • [1] ABE R, 1990, ONCOLOGY, V47, P65
  • [2] A HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAY WITH IMPROVED SELECTIVITY FOR CISPLATIN AND ACTIVE PLATINUM(II) COMPLEXES IN PLASMA ULTRAFILTRATE
    ANDREWS, PA
    WUNG, WE
    HOWELL, SB
    [J]. ANALYTICAL BIOCHEMISTRY, 1984, 143 (01) : 46 - 56
  • [3] PATTERNS OF HEARING-LOSS RESULTING FROM CISPLATINUM THERAPY
    BLAKLEY, BW
    MYERS, SF
    [J]. OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 1993, 109 (03) : 385 - 391
  • [4] CISPLATIN-INDUCED OTOTOXICITY - AUDIOMETRIC FINDINGS AND EXPERIMENTAL COCHLEAR PATHOLOGY
    BOHEIM, K
    BICHLER, E
    [J]. ARCHIVES OF OTO-RHINO-LARYNGOLOGY-ARCHIV FUR OHREN-NASEN-UND KEHLKOPFHEILKUNDE, 1985, 242 (01): : 1 - 6
  • [5] CAMPBELL K, 2000, ABSTR ASS RES OT, V23, P41
  • [6] D-Methionine protects against cisplatin damage to the stria vascularis
    Campbell, KCM
    Meech, RP
    Rybak, LP
    Hughes, LF
    [J]. HEARING RESEARCH, 1999, 138 (1-2) : 13 - 28
  • [7] D-Methionine provides excellent protection from cisplatin ototoxicity in the rat
    Campbell, KCM
    Rybak, LP
    Meech, RP
    Hughes, L
    [J]. HEARING RESEARCH, 1996, 102 (1-2) : 90 - 98
  • [8] Cloven NG, 2000, ANTICANCER RES, V20, P4205
  • [9] COLEMAN JK, 2001, ABSTR ASS RES OT, V24, P33
  • [10] COLEMAN JKM, 2002, M ABSTR ASS RES OT, V25, P226